Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

False Claims Act

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Community

Offices

Careers

Stay Connected

Our U.S. False Claim Act attorneys from multiple offices and practices firmwide have substantial experience handling False Claim Act investigations and litigation.

False Claims Act Attorneys

<h3>Sorry, we weren’t able to find the terms you entered.</h3>Please try a different term or keyword.

People

Capabilities

Resources

Not Found Cards

Case Studies

PACDL's 2025 White Collar Practice Seminar

Navigating DEI-Mitigating Risks and Protecting Corporate Values

Adam Braverman Leads Session on DOJ Enforcement at Pharmaceutical Compliance Forum's West Coast Members Meeting

Galia Amram, Carrie H. Cohen, Bonnie Lau, Haima Marlier, and Nate Mendell to Present “Investigations and Enforcement Update” to Aledade

Join MoFo for a Life Sciences CLE Webinar on AKS/FCA Enforcement Trends

Association of Corporate Counsel's 6th Annual All Day MCLE La-LAW-palooza

Events

True Facts About False Claims: MoFo's FCA Newsletter (October 2026)

Law360

Abbott FCA Deal Shows Enforcement Adequacy Quandaries

11th Circuit Rules False Claims Act’s Qui Tam Provisions Do Not Violate Appointments Clause of Constitution

MoFo’s State + Local Government Enforcement Newsletter (Spring 2026)

DOJ Launches West Coast Strike Force to Target Healthcare Fraud Across Arizona, Nevada, and Northern California

True Facts About False Claims: MoFo's FCA Newsletter (July 2025)

Insights

Bloomberg

Ex-DOJ Official Sees More False Claims Act Cases Getting Tossed

Paul Perkins, Former Associate Deputy Attorney General at the U.S. Department of Justice, Joins Morrison Foerster as a Partner

Three MoFo Partners Named 2025 Leaders of Influence in Law by the San Diego Business Journal

The AI Red Flags In DOJ Fraud Investigations

Boston Feds Must Do 'More With Less' On White Collar Front

SHRM

Justice Department Launches Civil Rights Fraud Initiative

News

Sign Up

Paul Perkins, former Associate Deputy Attorney General and Deputy Director of the Civil Fraud Section at the U.S. Department of Justice (DOJ), is a partner in Morrison Foerster’s Investigations + White Collar Defense Group and chair of the firm’s False Claims Act practice. Paul defends healthcare and life sciences companies, government contractors, and other clients in False Claims Act (FCA) investigations and litigation and related government enforcement actions. He also conducts internal investigations and advises on FCA compliance and voluntary disclosures. He brings more than 15 years of government and private practice experience, including senior DOJ leadership roles and an extensive record of personally building and litigating FCA cases, supervising complex matters, and negotiating nine-figure settlements. As Associate Deputy Attorney General, Paul oversaw the Civil Division and other Department components, shaped national FCA enforcement policy and priorities, and directed key FCA and other enforcement matters. As Deputy Director of the Civil Fraud Section, he supervised dozens of FCA matters, directing case strategy and settlement negotiations. His FCA experience includes matters involving the Anti-Kickback Statute, Medicare Advantage risk adjustment, medical necessity and billing, manufacturing compliance and product quality, and government contract costs. Paul draws on this combination of leadership and case experience to assess the government’s legal theories and evidence, develop defenses, and position matters for declination, dismissal, or resolution. He helps clients respond to inquiries and civil investigative demands, manage parallel civil and criminal exposure, and pursue favorable outcomes efficiently while limiting business disruption and collateral consequences. <h4>Representative Experiences </h4>Selected experience before joining Morrison Foerster includes: <ul><li>Negotiated the United States’ nine-figure FCA settlement with a global healthcare company concerning alleged noncompliance with manufacturing requirements. </li><li>Defended a major pharmaceutical company in parallel civil and criminal DOJ investigations involving alleged off-label promotion and improper financial relationships with physicians. Managed key aspects of the company’s response to DOJ and internal investigation, including interviewing employees, coordinating document productions, and preparing reverse proffers. </li><li>Supervised nationwide FCA investigations, litigation, and settlements under DOJ’s Civil Rights Fraud Initiative involving alleged noncompliance with federal civil rights and anti-discrimination requirements. </li><li>Directed DOJ’s civil FCA and criminal investigations, litigation, and resolutions involving hospitals and other healthcare providers concerning alleged billing fraud and noncovered services. </li><li>Supervised DOJ’s FCA investigation of a national pharmacy chain’s alleged improper dispensing of controlled substances and related false claims, directing negotiations that resulted in a nine-figure resolution. </li><li>Represented the United States in Medicare Advantage risk adjustment litigation against a national health insurer, briefing and arguing motions, coordinating the government’s discovery responses, conducting witness interviews, and preparing witnesses and defending depositions. </li></ul><ul><li>Represented the United States in a multimillion-dollar FCA settlement with a defense contractor concerning alleged overcharging of material costs under government contracts. </li><li>Led DOJ investigations of clinical laboratories from inception and negotiated multimillion-dollar settlements involving alleged kickbacks, medically unnecessary testing, and improper billing. Negotiated related civil resolutions with owners, investors, and a billing company, and coordinated the civil matters with parallel criminal proceedings. </li><li>Led an FCA investigation through government intervention and the filing of a complaint against laboratory executives involving alleged kickbacks and medically unnecessary testing. </li><li>Supervised DOJ’s FCA investigation of a healthcare provider concerning alleged kickbacks in patient recruitment and directed negotiations resulting in a multimillion-dollar settlement. </li><li>Supervised DOJ’s FCA investigation of a hospital concerning Medicare coverage requirements and directed negotiations resulting in a multimillion-dollar settlement. </li><li>Negotiated the United States’ nine-figure civil settlement with a global technology company in consumer protection litigation. </li></ul>Paul’s leadership work at DOJ included developing the Civil Rights Fraud Initiative and helping to formulate the policies on sub-regulatory guidance and qui tam dismissal reflected in the 2026 Justice Manual revisions. His extensive experience evaluating requests under 31 U.S.C. § 3730(c)(2)(A) informs his advice to clients seeking DOJ dismissal of declined qui tam actions. During his four years as Deputy Director of the Civil Fraud Section, Paul served as a career member of the Senior Executive Service and helped lead the Civil Fraud Section’s more than 150 attorneys and professional staff. During that period, DOJ obtained more than $13 billion in FCA settlements and judgments. His work included dozens of depositions and witness interviews and coordination with U.S. Attorneys’ Offices, investigative agencies, and criminal prosecutors. He used data analytics to identify potential fraud schemes and develop investigations that resulted in settlements. That experience helps him assess the data and assumptions underlying government and whistleblower allegations. His other DOJ roles included Chief of Staff and Special Counsel to the Assistant Attorney General for the Civil Division, Senior Counsel to the Deputy Attorney General, and Trial Attorney in the Civil Fraud Section. Before DOJ, Paul spent five years at a global law firm handling corporate investigations and complex civil litigation. He clerked for the Honorable Leslie H. Southwick of the U.S. Court of Appeals for the Fifth Circuit and began his career in the U.S. Senate and the White House Counsel’s Office.

Paul Perkins

Partner

Adam L. Braverman is a partner in Morrison Foerster’s Investigations + White Collar Defense practice. Adam formerly served as an Associate Deputy Attorney General for the U.S. Department of Justice (DOJ) and as the U.S. Attorney for the Southern District of California. Adam has represented public and private companies and their executives in complex government-facing probes, which have resulted in favorable outcomes and declinations by the government. He also represents boards of directors and companies in conducting complex internal investigations and compliance reviews. He has particular experience representing clients in investigations related to the False Claims Act (FCA) and Anti-Kickback Statute (AKS), procurement fraud, bribery, and national security, among other issues. He has successfully represented public companies and their boards of directors and officers in SEC enforcement actions and securities class actions. Adam also designs compliance policies on behalf of corporate clients and conducts trainings to ensure best practices in light of recent revisions to DOJ’s Evaluation of Corporate Compliance Programs and Corporate Criminal Enforcement Policies.Additionally, Adam advises clients on all aspects of complex commercial litigation in federal and state trial and appellate courts and in arbitration. He has represented clients in actions involving breaches of contracts and a wide array of complex commercial disputes.Before joining MoFo, Adam spent 13 years at DOJ, where he served in senior-level leadership positions in multiple administrations. As an Associate Deputy Attorney General, he advised the Deputy Attorney General on litigation and policy matters and was designated to coordinate DOJ’s efforts to investigate and prosecute fraud in connection with COVID-19 and CARES Act relief funds. During his tenure, he worked closely with all of DOJ’s law enforcement agencies, other federal agencies, INTERPOL, and state and local law enforcement agencies and associations.Adam also served as U.S. Attorney for the Southern District of California, where he managed one of the largest and busiest U.S. Attorney’s Offices in the country, comprised of nearly 300 employees. In this role, Adam was responsible for enforcing all violations of federal law in the district and defending the nation in all civil lawsuits. Prior to becoming U.S. Attorney, Adam was an Assistant U.S. Attorney and Deputy Chief, leading complex investigations and prosecutions of large-scale international criminal organizations. Prior to joining the government, Adam was an associate at a leading global law firm, where he dedicated his practice to civil litigation, white collar criminal cases, and internal investigations.Adam received his J.D. from the George Washington University School of Law and his B.A., cum laude, from the George Washington University.<h4>Representative Experience</h4><ul><li>A major U.S. defense contractor in an FCA matter involving allegations of fraudulent billing and workplace misconduct by a former employee in which the government declined to intervene and the relator dismissed the matter.</li><li>A small U.S. defense contractor in an FCA matter involving allegations of fraudulent billing and misrepresentations on grant applications in which the government closed its investigation.</li><li>A major U.S. defense contractor in an FCA matter involving allegations of fraudulent billing in which the court granted a motion to dismiss the matter.</li><li>An international defense contractor in a DOJ criminal investigation of allegations of bribery, wire fraud, and money laundering in which the government closed its investigation.</li><li>A major U.S. defense contractor in an investigation involving allegations of U.S. sanctions violations in which the government took no action.</li><li>A large for-profit college in multiple investigations involving allegations that the company improperly received and used federal funds in which the government closed its investigation.</li><li>An individual investigated by DOJ for alleged criminal violations of International Traffic in Arms Regulations in which the government closed its investigation.</li><li>A public company in a Securities Exchange Act Section 14(a) challenge to a proxy statement alleging material omissions in which the court denied a preliminary injunction and granted a motion to dismiss the case.</li><li>Healthcare organizations and private equity firms in FCA matters involving fraudulent billing and kickback allegations. </li><li>A professional sports team in a government investigation in which the government closed its investigation.</li><li>An entity in connection with the sale of a portion of a professional sports team.</li></ul>

Adam Braverman

Demme Doufekias is a trial attorney whose practice focuses on matters involving complex government and internal investigations. As a member of the firm’s Investigations + White-Collar Defense practice, individuals and corporations seek Demme’s counsel through all phases of investigations and litigation, from proactive compliance counseling and due diligence through the simultaneous defense of criminal investigations, administrative proceedings, and civil litigation. She successfully defends clients in civil and criminal matters in federal and state trials.Demme’s global investigations practice encompasses a number of substantive areas, including the Foreign Corrupt Practices Act and other anticorruption regimes, anti-money laundering, and criminal antitrust and securities violations. She has represented clients in cross-border investigations, including FCPA investigations and the U.S. Department of Justice’s (DOJ) investigations of price-fixing in the auto parts and generic drug industries. She also counsels clients in creating global anti-corruption compliance programs and in due diligence matters related to healthcare and anti-corruption laws.Demme regularly represents pharmaceutical, biotechnology, and medical device companies and has extensive experience with healthcare investigations and regulatory matters. She defends companies and executives in federal investigations conducted by DOJ, the Department of Health and Human Services, and the Food and Drug Administration. Her experience includes counseling and defending clients in matters related to the Food, Drug, and Cosmetic Act; other federal health care laws; and transparency laws such as the federal Physician Payments Sunshine Act. When required, Demme has successfully defended her healthcare clients at trial, including, obtaining a complete defense victory on behalf of a former pharmaceutical sales executive charged with violations of the federal Anti-Kickback statute in a two-week jury trial in U.S. District Court for the District of Massachusetts (U.S. v. Bruens, et al).Demme was most recently named to Global Investigations Review’s “Women in Investigations” 2018 survey, which recognizes the top 100 leading female investigations specialists from around the world.In addition to her investigations and healthcare practices, Demme maintains a robust civil litigation practice. Her experience includes conducting investigations and litigating on behalf of creditors’ committees and other constituents in federal bankruptcy matters and representing clients in state and federal civil trials.Prior to law school, Demme worked in the White House Counsel’s Office during the Clinton administration, where she worked on various investigations by the Office of Independent Counsel, including Whitewater, campaign finance, presidential impeachment, and the activities of various Cabinet members. She is admitted to practice in Virginia and the District of Columbia.<h4>Representative Experience</h4><h5>Criminal Investigations and Matters</h5><ul><li>Represents Fortune 500 multinational pharmaceutical company in DOJ and SEC investigations of potential FCPA violations.</li><li>Represented numerous executives of Japanese auto parts manufacturers in connection with DOJ investigation of price-fixing in the auto parts industry.</li><li>Represented Fortune 500 technology company on various FCPA matters in multiple emerging markets.</li><li>Represented software creator in connection with grand jury investigation of WikiLeaks.</li><li>Represented global power company in connection with FERC investigation of gas-trading practices.</li><li>Represented the former chairman and chief executive officer of Kansas public utility in DOJ and IRS investigations, related shareholder litigation and arbitration proceedings, resulting in two criminal trials, with the first ending in a hung jury and the second in a conviction later reversed on appeal and subsequently dismissed.</li></ul><h5>Health Care Fraud And False Claims Act Matters</h5><ul><li>Represents executive of generic drug manufacturer in connection with DOJ price-fixing investigation.</li><li>Represented former compliance director and marketing director of global pharmaceutical company in criminal investigation of marketing and promotion of arthritis pain medication.</li><li>Represented former president of a global medical device company indicted as “responsible corporate officer” in criminal investigation concerning off-label promotion of prosthetic bone cement.</li><li>Represented former senior executive of a Fortune 500 health care and pharmaceutical company during investigation of company’s good manufacturing practices (GMP) and related product recall.</li><li>Represented executive of large regional retina practice in qui tam litigation concerning Medicare and Medicaid reimbursement violations.</li></ul><h5>Bankruptcy And Other Litigation Matters</h5><ul><li>Conducted investigations on behalf of the official committee of unsecured creditors in various bankruptcy matters in the coal industry, including Murray Energy, Westmoreland Coal Company, Patriot Coal Corporation, Peabody Energy, Inc., and Armstrong Energy, Inc.</li><li>Conducted investigation on behalf of the official committee of unsecured creditors for international telecom company Avaya Inc. and its affiliated debtors.</li><li>Conducted investigation, on behalf of Chapter 11 Trustee, into collapse of global financial broker MF Global and brought suit against former officers and directors for breaches of various duties.</li><li>Represented government contractor specializing in technologies for national security and aerospace programs in trade secrets litigation, including at trial in state court litigation and winning a partial defense verdict.</li><li>Obtained defense judgment for a national law firm in a $226 million state legal malpractice suit.</li></ul>

Demme Doufekias

When Your Life Sciences Are on the Line: AI and the FDA

When Your Life Sciences Are on the Line: False Claims Act

MoForecast: State AGs and the False Claims Act: Navigating Multijurisdictional Challenges and Investor Scrutiny

False Claims Act

Insights

Insights

News

News

Events

Events

Podcasts

Podcasts